Opinion|Videos|August 19, 2024
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Experts discuss future directions of BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
- How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
5 Things to Know About the Oral GLP-1 Era
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5
